ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The dual role of the PI3K/AKT/mTOR axis in glial cell survival and neuroinflammation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is characterized by a triad of inflammation, demyelination, and neurodegeneration, yet current disease-modifying therapies are limited in their ability to halt progressive neurodegeneration or promote remyelination. The PI3K/AKT/mTOR signaling pathway is a master regulator of these divergent cellular processes and therefore represents a biological paradox in multiple sclerosis. In the pathogenic facet of the disease, activation of this axis supports the differentiation and effector functions of pro-inflammatory T- and B-cells and contributes to inflammatory programs in microglia and macrophages. In the regenerative facet, physiological PI3K/AKT/mTOR activity is required for oligodendrocyte precursor-cell survival, differentiation, myelin synthesis, and maintenance of myelin integrity. Astrocytic signaling adds another layer of context-dependence, with pathway activity influencing reactive gliosis and the inflammatory or reparative properties of the lesion environment. Consequently, systemic inhibition of the pathway may suppress neuroinflammation while simultaneously interfering with endogenous repair. This review therefore considers PI3K/AKT/mTOR axis according to these opposing pathogenic and protective functions, highlighting the importance of cell type, disease stage, and treatment timing. Precision strategies capable of selectively suppressing inflammatory signaling while preserving or restoring pro-regenerative activity, potentially through cell-specific molecular targets, may provide a more rational therapeutic approach than generalized pathway inhibition.
Indexed as
Identifiers
42888316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.